Press releases
US-specific press releases are available here. Please visit our global website for access to global press releases dating back to 2009.
-
Changing attitudes to vaccination after the COVID-19 pandemic could increase adult vaccination rates, improving health outcomes over the longer term
Survey shows that people 50 years of age and older value good health and improved quality of life.
Read more -
ViiV Healthcare to present key data that provides further support for the use of 2-drug regimens, including long-term efficacy, alongside new insights into living with HIV at IDWeek 2021
ViiV Healthcare announce the presentation of 13 abstracts from its portfolio of pipeline prevention options.
Read more -
GSK announces major renewable energy investment and low carbon inhaler programme alongside Life Sciences sector Race to Zero ‘breakthrough’ at NYC Climate Week
Company announces £50m investment in renewable energy and carbon reduction at major UK and US manufacturing sites.
Read more -
GSK to highlight continued progress in oncology pipeline and portfolio with data presented at ESMO
GSK to highlight continued progress in oncology pipeline and portfolio with data presented at ESMO
Read more -
SK bioscience and GSK start Phase 3 trial of adjuvanted COVID-19 vaccine candidate
Advance to Phase 3 follows positive interim Phase 1/2 immunogenicity and safety data
Read more -
GSK announces “Ask2BSure” public health awareness campaign for meningitis B vaccination
GSK launches “Ask2BSure,” to encourage parents to talk with their child’s doctor to be sure if they have received meningitis B vaccination.
Read more -
GSK receives FDA accelerated approval for JEMPERLI (dostarlimab-gxly) for adult patients with mismatch repair-deficient (dMMR) recurrent or advanced solid tumors
GSK receives FDA accelerated approval for JEMPERLI for adult patients with mismatch repair-deficient recurrent or advanced solid tumors
Read more -
Second-Generation mRNA COVID-19 Vaccine Candidate, CV2CoV, Demonstrates Improved Immune Response and Protection in Preclinical Study
Preclinical study provides evidence for strongly improved immune responses with second-generation mRNA backbone
Read more -
GSK files for licensure of MMR vaccine in the US
GSK seeks US approval of PRIORIX vaccine licensed in more than 100 countries.
Read more -
GSK announces FDA approval for Nucala (mepolizumab) for use in adults with chronic rhinosinusitis with nasal polyps
Fourth indication for mepolizumab in the US for eosinophil-driven diseases.
Read more -
GSK delivers strong Q2 sales of £8.1 billion, +6% AER, +15% CER Total EPS 27.9p -39% AER, -28% CER; Adjusted EPS 28.1p +46% AER +71% CER
Sales growth driven by strong commercial execution and favourable prior year comparison
Read more -
Shingrix approved in the US for prevention of shingles in immunocompromised adults
Shingrix approved in the US for prevention of shingles in immunocompromised adults
Read more -
GSK begins shipping another record supply of influenza vaccine for 2021-22 season in US
GSK increases its volume of influenza vaccines in 2021 to support immunization during pandemic.
Read more -
ViiV Healthcare study shows new long-acting HIV regimen Cabenuva (cabotegravir/rilpivirine) can be successfully implemented in broad range of US healthcare practices, even during COVID-19
ViiV Healthcare today presented positive findings from the CUSTOMIZE trial
Read more -
ViiV Healthcare to present new data from diverse portfolio and pipeline of 2-drug and long-acting regimens for HIV treatment and prevention at IAS 2021
Data to be presented underscore the commitment to developing innovative treatment and prevention options
Read more -
GSK and iTeos Therapeutics announce development and commercialisation collaboration for EOS-448, an anti-TIGIT monoclonal antibody, enabling novel next-generation immuno-oncology combinations
GSK now has the leading portfolio of antibodies targeting the CD226 axis - a key target for next-generation immuno-oncology therapies
Read more -
GSK to showcase scientific advances and progress in oncology at ASCO and EHA
GSK will showcase innovative approaches to oncology R&D and cutting-edge science at the upcoming ASCO and EHA meetings.
Read more -
Sanofi and GSK initiate global Phase 3 clinical efficacy study of COVID-19 vaccine candidate
Pending positive Phase 3 outcomes and regulatory reviews, the vaccine could be approved in Q4 2021
Read more -
GSK and Vir Biotechnology announce sotrovimab (VIR-7831) receives Emergency Use Authorization from the US FDA for treatment of mild-to-moderate COVID-19 in high-risk adults and pediatric patients
GSK and Vir Biotechnology announce sotrovimab (VIR-7831) receives Emergency Use Authorization from the US FDA
Read more -
GSK announced as a Principal Partner of COP26 UN Climate Change Conference
As Principal Partner, GSK will drive action on climate, nature and health targets in support of COP26 ambitions.
Read more
Find out more about us
-
About us
We are a science-led global healthcare company with a special purpose: to help people do more, feel better, live longer.
-
Products
We make a wide range of prescription medicines, vaccines and consumer healthcare products.
-
Research and development
Driving scientific innovation to deliver the next generation of transformational medicines and vaccines for patients.
